Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of TNFalpha blockade on specific B cell responses in spondyloarthropathy
2004-001113-33Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Jul 2005
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of infliximab and etanercept in spondyloarthritis (SpA) (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Serum antibody titers. Started Jul 2005; status: completed.
02
Drugs
infliximabetanercept
03
Conditions
spondyloarthritis (SpA)
Beyond the preview
Go deeper on 2004-001113-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001113-33.